{"id":"W4402704918","doi":"10.1016/j.annonc.2024.08.1722","title":"1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Abiraterone; Urology; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008708345,0.001997906,0.002506088,0.0004961002,0.000395427,0.0009119075,0.0007556324,0.001086259,0.00686541],"category_scores_gemma":[0.0006406878,0.0006652657,0.001135331,0.000392713,0.0009249886,0.0008377595,0.0003237447,0.003283788,0.001268227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008894103,"about_ca_system_score_gemma":0.001479634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00238082,"about_ca_topic_score_gemma":0.006161714,"domain_scores_codex":[0.9997676,0.0001021453,0.000007261288,0.0000425195,0.00001662512,0.00006392967],"domain_scores_gemma":[0.9996965,0.00004479967,0.00004903839,0.00001710124,0.00001873581,0.0001739611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9257806,0.01580264,0.00116206,0.0004055847,0.0008474574,0.0000858353,0.00006396178,0.001007679,0.01198373,0.0002173769,0.00344276,0.03920034],"study_design_scores_gemma":[0.7434428,0.2444848,0.006635348,0.00003172635,0.0006269385,0.0001153274,0.00004567436,0.0008730376,0.00132924,0.0002613382,0.002123428,0.00003041252],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890737,0.002582294,0.000420714,0.0009401379,0.0003696456,0.001301513,0.001754115,0.0002586061,0.003299257],"genre_scores_gemma":[0.983055,0.002584237,0.001305384,0.0009945626,0.0003025684,0.001363973,0.002776881,0.00005051952,0.00756676],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00686541,"threshold_uncertainty_score":0.0229671,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1336092074318502,"score_gpt":0.4620167032676954,"score_spread":0.3284074958358452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}